Real-world Evidence for Enfortumab Vedotin in Patients with Metastatic Urothelial Cancer: An Austrian Multicentre Study DOI Creative Commons

Dora Niedersuess-Beke,

Karl Mayrhofer,

Johanna Krauter

et al.

Clinical Genitourinary Cancer, Journal Year: 2024, Volume and Issue: unknown, P. 102278 - 102278

Published: Nov. 1, 2024

Language: Английский

Pre-treatment metastatic biopsy: a step towards precision oncology for urothelial cancer DOI
Niklas Klümper, Alexander Cox, Gottfrid Sjödahl

et al.

Nature Reviews Urology, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 29, 2024

Language: Английский

Citations

1
Targeted Therapeutic Strategies for Nectin-4 in Breast Cancer: Recent Advances and Future Prospects DOI Open Access
Yufei Wang, Guangliang Li, Han-Ying Wang

et al.

The Breast, Journal Year: 2024, Volume and Issue: 79, P. 103838 - 103838

Published: Nov. 14, 2024

Nectin-4 is a cell adhesion molecule which has gained more and attention as therapeutic target in cancer recently. Overexpression of been observed various tumors, including breast cancer, associated with tumor progression. Enfortumab vedotin(EV)is an antibody-drug conjugate (ADC) targeting Nectin-4, approved by FDA for the treatment urothelial carcinoma. Notably, was also investigated preclinical clinical settings. Nectin-4-targeted approaches, such ADCs, oncolytic viruses, photothermal therapy immunotherapy, have shown promising results early-phase trials. These therapies offer novel strategies delivering targeted treatments to Nectin-4-expressing cells, enhancing efficacy minimizing off-target effects. In conclusion, this review aims provide overview latest advances understanding role discuss future development prospects agents.

Language: Английский

Citations

1
Molecular Classification of Urothelial Carcinoma DOI
Jie‐Fu Chen, Hikmat Al‐Ahmadie

Surgical pathology clinics, Journal Year: 2024, Volume and Issue: 18(1), P. 41 - 51

Published: Nov. 19, 2024

Language: Английский

Citations

0
Targeted therapies and molecular targets in the therapeutic landscape of advanced urothelial carcinoma: state of the art and future perspectives DOI Creative Commons

Irene Testi,

Giulia Claire Giudice, Giuseppe Salfi

et al.

Exploration of Targeted Anti-tumor Therapy, Journal Year: 2024, Volume and Issue: 5(6), P. 1326 - 1364

Published: Nov. 21, 2024

Advanced urothelial carcinoma (aUC) has a dismal prognosis, with 5-year survival rate of approximately 10%. Platinum-based chemotherapy been the backbone first-line treatment aUC for over 40 years. Only in last decade, evolved and enriched new classes drugs that demonstrated pivotal improvements terms oncological responses and, ultimately, survival. Thus, approach to is becoming more tailored single patient, particularly owing targeted therapies, such as fibroblast growth factor receptor (FGFR) inhibitors, antibody-drug conjugates (ADCs) targeting TROP2 Nectin-4, anti-Her-2 therapies others. However, due rapidly evolving scenario, optimal sequence systemic unknown several important research questions remain unanswered, including identification reliable biomarkers guide decisions. Through ongoing clinical trials, we can continue refine personalized strategies ultimately enhance patient care this challenging disease setting. In review, provide comprehensive overview current emerging landscape aUC. We delved into opportunities challenges presented by approaches explored potential future directions field.

Language: Английский

Citations

0
Real-world Evidence for Enfortumab Vedotin in Patients with Metastatic Urothelial Cancer: An Austrian Multicentre Study DOI Creative Commons

Dora Niedersuess-Beke,

Karl Mayrhofer,

Johanna Krauter

et al.

Clinical Genitourinary Cancer, Journal Year: 2024, Volume and Issue: unknown, P. 102278 - 102278

Published: Nov. 1, 2024

Language: Английский

Citations

0